BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...Cellectis S.A. (NASDAQ:CLLS), which started clinical testing of its first allogeneic CAR T cell therapy UCART19...
BioCentury | Oct 11, 2019
Targets & Mechanisms

CAR Ts can move well beyond cancer, but will need to go allogeneic first

...“Allogeneic CARs on the Horizon” ). The most advanced allogeneic CAR Ts in oncology are UCART19...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...Therapeutics Inc. is presenting data on additional patients treated with its TALEN-edited allogeneic CD19 CAR, UCART19...
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...“more antibody-ish.” Cellectis was an early adopter of allogeneic CAR T cells. Its lead product, UCART19...
...product Allogeneic technology description Technology Phase of development Gene editing Allogene Therapeutics Inc. (NASDAQ:ALLO); Servier UCART19...
BioCentury | Oct 12, 2018
Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

...S.A. (Euronext:ALCLS; NASDAQ:CLLS). In April, Allogene assumed rights to the product portfolio, including lead program UCART19...
...in Allogene’s series A round (see "Self-Driving Cars" ). Allogene has exclusive, U.S. rights to UCART19...
...including the exercise of the underwriters' overallotment. Allogene Therapeutics Inc. (NASDAQ:ALLO), South San Francisco, Calif. Sandi Wong UCART19...
BioCentury | Oct 11, 2018
Financial News

First-day pop for Allogene after year's largest biotech IPO on NASDAQ

...S.A. (Euronext:ALCLS; NASDAQ:CLLS). In April, Allogene assumed rights to the product portfolio, including lead program UCART19...
...in Allogene’s series A round (see "Self-Driving Cars" ). Allogene has exclusive, U.S. rights to UCART19...
...Inc. (NASDAQ:RUBY), which in July raised $277.3 million, including the exercise of the underwriters' overallotment. Sandi Wong UCART19...
BioCentury | Oct 5, 2018
Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

...allogeneic CAR T products spun out from Pfizer Inc. (NYSE:PFE) in April, including lead program UCART19...
BioCentury | Oct 2, 2018
Financial News

Allogene IPO could be year's largest biotech listing on NASDAQ

...allogeneic CAR T products spun out from Pfizer Inc. (NYSE:PFE) in April, including lead program UCART19...
BioCentury | Sep 21, 2018
Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

...from Pfizer Inc. (NYSE:PFE) in April, including lead program UCART19. Pfizer had held rights to UCART19...
...is co-founder and senior managing director; Gilead; and Chang. Allogene has exclusive, U.S. rights to UCART19...
...in 2H19. The company's pipeline also includes ALLO-501, which is identical in molecular design to UCART19...
BioCentury | Sep 14, 2018
Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

...allogeneic CAR T products spun out from Pfizer Inc. (NYSE:PFE) in April, including lead program UCART19...
...is co-founder and senior managing director; Gilead; and Chang. Allogene has exclusive, U.S. rights to UCART19...
...in 2H19. The company's pipeline also includes ALLO-501, which is identical in molecular design to UCART19...
Items per page:
1 - 10 of 58